AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28917688 — intervention group
Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 253
Study 27702766 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 64
Study 27702766 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 64
Study 25917024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous povidone-iodine solution (Group I)
Number of subjects: 1326
Study 25917024 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic povidone-iodine solution (Group II)
Number of subjects: 1326
Study 23713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric exposure (HYPO; 574 mmHg approximately 8000 ft)
Number of subjects: 27
Study 23713213 — intervention group
Group type: COMPARATOR
Intervention: Normobaric conditions (NORM)
Number of subjects: 27
Study 23713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric exposure (HYPO)
Number of subjects: 27
Study 20500100 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose polytherapy (metformin 850 mg/day, flutamide 62.5 mg/day, pioglitazone 7.5 mg/day, ethinylestradiol 20 μg/day, drospirenone 3 mg/day)
Number of subjects: 36
Study 20500100 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose polytherapy
Number of subjects: 36
Study 17825587 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokin
Number of subjects: 167
Study 17825587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 167
Study 16815486 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral formula (IEEF) for 12 weeks
Number of subjects: 30
Study 16815486 — intervention group
Group type: COMPARATOR
Intervention: Regular polymeric enteral formula (control group) for 12 weeks
Number of subjects: 30
Study 12788419 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate (OCA)
Number of subjects: 50
Study 10357340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM administered 30 min before skin incision (Group B)
Number of subjects: 90
Study 10357340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM administered after gallbladder removal (Group A)
Number of subjects: 90
Study 10357340 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (CPM) 20 mg IM administered 30 min before skin incision (Control group)
Number of subjects: 90
Study 9545876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.0
Number of subjects: 0
Study 9545876 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus
Number of subjects: 0
Study 9545876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2 (30 seconds application)
Number of subjects: 0
Study 9545876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2 (60 seconds application)
Number of subjects: 0
Study 1771934 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg/d for 4 weeks (n = 13)
Number of subjects: 50
Study 1771934 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12)
Number of subjects: 50
Study 1771934 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole plus BSS for 4 weeks (n = 13)
Number of subjects: 50
Study 1771934 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)
Number of subjects: 50
Study 7137520 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystallinic theophylline
Number of subjects: 8
Study 7137520 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolair
Number of subjects: 8
Study 7137520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuelin
Number of subjects: 8
Study 7137520 — intervention group
Group type: EXPERIMENTAL
Intervention: Teovent
Number of subjects: 8
Study 7137520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphylline
Number of subjects: 8
Study 7137520 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline inhalations (5 doses)
Number of subjects: 8
Study 30217374 — intervention group
Group type: EXPERIMENTAL
Intervention: One-catheter concepts (OCC) using Tiger II or BLK catheters
Number of subjects: 300
Study 30217374 — intervention group
Group type: COMPARATOR
Intervention: Two-catheter concepts (TCC) using standard Judkins catheters
Number of subjects: 300
Study 26227996 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - energy intake subscale
Number of subjects: 404
Study 26227996 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - energy expenditure subscale
Number of subjects: 404
Study 26227996 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - self-monitoring subscale
Number of subjects: 404
Study 26227996 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - self-regulation subscale
Number of subjects: 404
Study 24894410 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried broccoli sprouts (90 mg of active sulforaphane, 15 capsules per day)
Number of subjects: 40
Study 24894410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive substances, mainly methylcellulose, same capsule size and portion distribution)
Number of subjects: 40
Study 22277664 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml kg(‐1) diluted raspberry syrup
Number of subjects: 14
Study 22277664 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 ml kg(‐1) diluted raspberry syrup
Number of subjects: 14
Study 20625111 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (target dose 0.4 mg . kg(‐1) . d(‐1))
Number of subjects: 230
Study 20625111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 20625111 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230
Study 18563971 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening
Number of subjects: 32
Study 18563971 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing
Number of subjects: 32
Study 18563971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm tapping
Number of subjects: 32
Study 18563971 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard playing
Number of subjects: 32
Study 15793606 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 0‐(beta‐hydroxyethyl)‐rutosides (1 g/day)
Number of subjects: 22
Study 15793606 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 0‐(beta‐hydroxyethyl)‐rutosides (2 g/day)
Number of subjects: 22
Study 11989827 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 60
Study 11989827 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 60
Study 10431768 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1a treatment
Number of subjects: 68
Study 7593528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg gemeprost by vaginal pessary (group I)
Number of subjects: 800
Study 7593528 — intervention group
Group type: COMPARATOR
Intervention: 600 micrograms misoprostol by mouth (group II)
Number of subjects: 800
Study 7593528 — intervention group
Group type: COMPARATOR
Intervention: 600 micrograms misoprostol (group II)
Number of subjects: 800
Study 2259825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2.5 mg) with saline to complete 3 ml given through a jet nebulizer; followed by an additional dose (1 mg) through a 500 ml spacer 30 minutes later
Number of subjects: 44
Study 2259825 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (2.5 mg) with saline to complete 3 ml given through a spacer first; followed by an additional dose (1 mg) through a jet nebulizer 30 minutes later
Number of subjects: 44
Study 6777705 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% Sorbitol
Number of subjects: 53
Study 6777705 — intervention group
Group type: COMPARATOR
Intervention: 20% Mannitol
Number of subjects: 53
Study 6357964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate tablets
Number of subjects: 40
Study 6357964 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 40
Study 31325625 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVAD
Number of subjects: 141
Study 31325625 — intervention group
Group type: COMPARATOR
Intervention: BKP
Number of subjects: 141
Study 30572939 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT + TME
Number of subjects: 192
Study 30572939 — intervention group
Group type: COMPARATOR
Intervention: TME
Number of subjects: 192
Study 27124116 — intervention group
Group type: EXPERIMENTAL
Intervention: Left temporal area anodal (LTA) or bifrontal tDCS stimulation (2 mA)
Number of subjects: 43
Study 27124116 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (0.3 mA)
Number of subjects: 43
Study 25125014 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal balloon occlusion
Number of subjects: 100
Study 25125014 — intervention group
Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 100
Study 25125014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with new cerebral ischemic lesions on DW-MRI
Number of subjects: 100
Study 25125014 — intervention group
Group type: COMPARATOR
Intervention: Patients without DW-MRI lesions
Number of subjects: 100
Study 22674146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) - epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) for 4 cycles (EC-T)
Number of subjects: 95
Study 22674146 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) - exemestane 25 mg daily for 24 weeks (combined with goserelin in premenopausal patients)
Number of subjects: 95
Study 22674146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 95
Study 22674146 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT)
Number of subjects: 95
Study 20237055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-film-coated catheter (FCC)
Number of subjects: 77
Study 20237055 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter (SC)
Number of subjects: 77
Study 18773752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss (specific details not provided)
Number of subjects: 0
Study 16214025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental tasks (psychological stress)
Number of subjects: 32
Study 11844818 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus weekly CDDP chemotherapy (40 mg/m(2))
Number of subjects: 259
Study 11844818 — intervention group
Group type: COMPARATOR
Intervention: RT without chemotherapy
Number of subjects: 259
Study 10076721 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by adjusted locoregional treatment
Number of subjects: 0
Study 10076721 — intervention group
Group type: COMPARATOR
Intervention: Initial mastectomy followed by adjuvant chemotherapy
Number of subjects: 0
Study 10076721 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 7672547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd: YAG laser therapy
Number of subjects: 94
Study 7672547 — intervention group
Group type: COMPARATOR
Intervention: Injection-assisted piecemeal polypectomy
Number of subjects: 94
Study 2145233 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 40
Study 2145233 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 40
Study 6102561 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased psychiatrist/patient ratio
Number of subjects: 0
Study 6102561 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongesting the clinic
Number of subjects: 0
Study 31880343 — intervention group
Group type: EXPERIMENTAL
Intervention: VASE RESOLVE
Number of subjects: 0
Study 31880343 — intervention group
Group type: COMPARATOR
Intervention: RESOLVE with SMS
Number of subjects: 0
Study 30987987 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise and socialisation/health education + GAR (hearing education, communication strategies, psychosocial support)
Number of subjects: 71
Study 30987987 — intervention group
Group type: COMPARATOR
Intervention: GAR only
Number of subjects: 71
Study 27996339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowen systemic family therapy (eight 90‐minute sessions)
Number of subjects: 42
Study 27996339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 42
Study 26188742 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bites technique (5 mm every 5 mm)
Number of subjects: 560
Study 26188742 — intervention group
Group type: COMPARATOR
Intervention: Large bites technique (1 cm every 1 cm)
Number of subjects: 560
Study 26188742 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bites technique
Number of subjects: 560
Study 26188742 — intervention group
Group type: COMPARATOR
Intervention: Large bites technique
Number of subjects: 560
Study 23200124 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate treatment (PCT) ≥50 g oral carbohydrates 2-4 h pre-anaesthesia
Number of subjects: 1685
Study 23200124 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate treatment (PCT)
Number of subjects: 1685
Study 23200124 — intervention group
Group type: COMPARATOR
Intervention: Control (fasted/placebo)
Number of subjects: 1685
Study 19542525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/d)
Number of subjects: 76
Study 19542525 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg)
Number of subjects: 76
Study 18716688 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg tobramycin twice‐daily continuous treatment
Number of subjects: 32
Study 18716688 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tobramycin twice daily in cycles of 28 days on and 28 days off treatment
Number of subjects: 32
Study 18716688 — intervention group
Group type: COMPARATOR
Intervention: Colistin (control group)
Number of subjects: 32
Study 17152857 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg orally) given to female subjects 1 hour before post-TST
Number of subjects: 29
Study 17152857 — intervention group
Group type: COMPARATOR
Intervention: Placebo given to female subjects 1 hour before post-TST
Number of subjects: 29
Study 15314393 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 58
Study 15314393 — intervention group
Group type: COMPARATOR
Intervention: SP6 touch
Number of subjects: 58
Study 10790044 — intervention group
Group type: EXPERIMENTAL
Intervention: On-frequency condition (using signals from stage I to mask probes of the same frequency)
Number of subjects: 0
Study 10790044 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-frequency condition (using off-frequency maskers at levels determined in stage I to mask probes)
Number of subjects: 0
Study 10790044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined condition (using both on- and off-frequency maskers to mask probes)
Number of subjects: 0
Study 9311145 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted consequences (cursor moves freely with joystick)
Number of subjects: 0
Study 9311145 — intervention group
Group type: COMPARATOR
Intervention: Restricted consequences (cursor confined to track)
Number of subjects: 0
Study 8287567 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic GH replacement therapy (0.25 IU/kg/week)
Number of subjects: 20
Study 2882294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma), given by intravenous infusion twice a week for four weeks
Number of subjects: 18
Study 2882294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma)
Number of subjects: 18
Study 31385885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium Bromide 100 mg plus Simethicone 300 mg (PB+S)
Number of subjects: 285
Study 31385885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 30141237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (2 mg/day) of aripiprazole adjunctive to antidepressant therapy
Number of subjects: 0
Study 30141237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29119110 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmin (50mg/kg/day)
Number of subjects: 150
Study 29119110 — intervention group
Group type: COMPARATOR
Intervention: 20% 250ml mannitol (1g/kg/day) for 7 days and dexamethasone (10mg/day) for 3 days intravenously
Number of subjects: 150
Study 26316698 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets (one tablet), 15/650mg (two tablets), or 30/1,300mg (four tablets) under fasted conditions
Number of subjects: 151
Study 26316698 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets under fed conditions
Number of subjects: 151
Study 24079037 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol and dexamethasone added into WLL fluid
Number of subjects: 176
Study 24079037 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% sodium chloride solution in WLL)
Number of subjects: 176
Study 20076856 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg)
Number of subjects: 114
Study 20076856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 18194028 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP‐SD)
Number of subjects: 157
Study 16387583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 mug twice daily)
Number of subjects: 0
Study 16387583 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (5-10 mg nightly, age dependent)
Number of subjects: 0
Study 15057400 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (Group B)
Number of subjects: 19
Study 15057400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 19
Study 15057400 — intervention group
Group type: COMPARATOR
Intervention: No pre‐medication (Group A)
Number of subjects: 19
Study 11127161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (Zyban-GlaxoWellcome)
Number of subjects: 0
Study 11127161 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 0
Study 8985043 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR interstitial radiotherapy (70 Gy/4 to 9 days)
Number of subjects: 29
Study 8985043 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR interstitial radiotherapy (60 Gy/10 fractions/6 days)
Number of subjects: 29
Study 1473653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-teboroxime
Number of subjects: 16
Study 1473653 — intervention group
Group type: COMPARATOR
Intervention: TI-201
Number of subjects: 16
Study 3882899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital treatment (27 cases)
Number of subjects: 53
Study 3882899 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 cases)
Number of subjects: 53
Study 30326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant Learning (OL)
Number of subjects: 178
Study 30326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Conservation (EC)
Number of subjects: 178
Study 30452207 — intervention group
Group type: EXPERIMENTAL
Intervention: New value frameworks incorporating real-world evidence
Number of subjects: 0
Study 25796578 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 625
Study 25796578 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Number of subjects: 625
Study 25796578 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 625
Study 24669750 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed + Anastrozole (AI)
Number of subjects: 24
Study 24669750 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (AI)
Number of subjects: 24
Study 24669750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22053074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 44
Study 22053074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg/h)
Number of subjects: 44
Study 22053074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone + GTN
Number of subjects: 44
Study 22053074 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of antioxidant vitamin C with rosiglitazone and GTN
Number of subjects: 44
Study 22053074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20473738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanreqing Injection (TRQI)
Number of subjects: 90
Study 20473738 — intervention group
Group type: COMPARATOR
Intervention: Control group A (15 mg ambroxol hydrochloride twice a day)
Number of subjects: 90
Study 20473738 — intervention group
Group type: COMPARATOR
Intervention: Control group B (conventional Western medicine treatment only)
Number of subjects: 90
Study 18269068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment strategies for patients with acute decompensated heart failure and poor renal function
Number of subjects: 0
Study 18269068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra) for patients with heart failure and preserved left ventricular systolic function
Number of subjects: 0
Study 16294264 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 9496
Study 16294264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9496
Study 12412806 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate 70 mg
Number of subjects: 1258
Study 12412806 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly alendronate 35 mg
Number of subjects: 1258
Study 12412806 — intervention group
Group type: COMPARATOR
Intervention: Daily alendronate 10 mg
Number of subjects: 1258
Study 12412806 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 1258
Study 10902536 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ml of fresh milk (620mg Ca)
Number of subjects: 8